Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPK14 | Q16539 | 17/20 | 0.52 |
| ▸ | MAPK13 | O15264 | 5/20 | 0.51 |
| ▸ | MAPK12 | P53778 | 5/20 | 0.51 |
| ▸ | MAPK11 | Q15759 | 5/20 | 0.51 |
| ▸ | GCGR | P47871 | 3/20 | 0.51 |
| ▸ | HTR2A | P28223 | 1/20 | 0.42 |
| ▸ | HTR2C | P28335 | 1/20 | 0.42 |
| ▸ | MAPK10 | P53779 | 1/20 | 0.40 |
| ▸ | ALOX5 | P09917 | 2/20 | 0.40 |
| ▸ | SRC | P12931 | 1/20 | 0.38 |
| ▸ | BRAF | P15056 | 1/20 | 0.38 |
| ▸ | KDR | P35968 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1386881 | 0.90 | MAPK14 (0.47) | MAPK14MAPK13MAPK12MAPK11GCGR | |
| SCHEMBL2929805 | 0.86 | ADORA3 (0.43) | MAPK14MAPK13MAPK12MAPK11GCGR | |
| SCHEMBL1385819 | 0.83 | MAPK14 (0.44) | MAPK14MAPK13MAPK12MAPK11 | |
| SCHEMBL2931861 | 0.80 | MAPK14 (0.48) | MAPK14MAPK13MAPK12MAPK11GCGR | |
| SCHEMBL29652689 | 0.80 | MAPK14 (0.48) | MAPK14MAPK13MAPK12MAPK11GCGR | |
| SCHEMBL1386160 | 0.80 | MAPK14 (0.46) | MAPK14MAPK13MAPK12MAPK11GCGR | |
| SCHEMBL1386525 | 0.77 | MAPK14 (0.47) | MAPK14MAPK13MAPK12MAPK11GCGR | |
| SCHEMBL1386765 | 0.76 | MAPK14 (0.45) | MAPK14MAPK13MAPK12MAPK11 | |
| SCHEMBL1386446 | 0.75 | MAPK14 (0.49) | MAPK14MAPK13MAPK12MAPK11GCGR | |
| SCHEMBL1386721 | 0.75 | FGFR1 (0.45) | MAPK14MAPK13MAPK12MAPK11MAPK10 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8536194-B2 | Pyrazolopyridine derivates | PALAU PHARMA, S.A. (ES) | 2013-09-17 | — | — | US | claimed |
| EP-1611131-B1 | PYRAZOLOPYRIDINE DERIVATES | PALAU PHARMA SA (ES) | 2010-09-15 | — | — | EP | claimed |
| US-20090005377-A1 | Pyrazolopyridine Derivates | PALAU PHARMA, S.A. (ES) | 2009-01-01 | — | — | US | claimed |
| US-7468376-B2 | Pyrazolopyridine derivates | PALAU PHARMA, S.A. (ES) | 2008-12-23 | — | — | US | claimed |
| US-20060167040-A1 | Pyrazolopyridine derivates | J. URIACH Y COMPANIA S.A. (ES) | 2006-07-27 | — | — | US | claimed |
| EP-1611131-B1 | PYRAZOLOPYRIDINE DERIVATES | PALAU PHARMA SA (ES) | 2010-09-15 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060167040-A1 | Pyrazolopyridine derivates | MAPK1, MAP4K2, MAP4K3 | MAPK14 34/4885MAPK13 36/4885MAPK12 38/4885 |
| US-20090005377-A1 | Pyrazolopyridine Derivates | MAPK1, MAPK4, MAP4K2 | MAPK14 33/4885MAPK13 37/4885MAPK12 39/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.